BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 25010620)

  • 1. Inositol: history of an effective therapy for Polycystic Ovary Syndrome.
    Bizzarri M; Carlomagno G
    Eur Rev Med Pharmacol Sci; 2014 Jul; 18(13):1896-903. PubMed ID: 25010620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome.
    Dinicola S; Chiu TT; Unfer V; Carlomagno G; Bizzarri M
    J Clin Pharmacol; 2014 Oct; 54(10):1079-92. PubMed ID: 25042908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome.
    Unfer V; Porcaro G
    Expert Rev Clin Pharmacol; 2014 Sep; 7(5):623-31. PubMed ID: 24898153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.
    Nordio M; Proietti E
    Eur Rev Med Pharmacol Sci; 2012 May; 16(5):575-81. PubMed ID: 22774396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reflections on inositol(s) for PCOS therapy: steps toward success.
    Nestler JE; Unfer V
    Gynecol Endocrinol; 2015 Jul; 31(7):501-5. PubMed ID: 26177098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential role and therapeutic interests of myo-inositol in metabolic diseases.
    Croze ML; Soulage CO
    Biochimie; 2013 Oct; 95(10):1811-27. PubMed ID: 23764390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients.
    Monastra G; Unfer V; Harrath AH; Bizzarri M
    Gynecol Endocrinol; 2017 Jan; 33(1):1-9. PubMed ID: 27898267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inositol as putative integrative treatment for PCOS.
    Genazzani AD
    Reprod Biomed Online; 2016 Dec; 33(6):770-780. PubMed ID: 27717596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction.
    Papaleo E; Unfer V; Baillargeon JP; De Santis L; Fusi F; Brigante C; Marelli G; Cino I; Redaelli A; Ferrari A
    Gynecol Endocrinol; 2007 Dec; 23(12):700-3. PubMed ID: 17952759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bye-bye chiro-inositol - myo-inositol: true progress in the treatment of polycystic ovary syndrome and ovulation induction.
    Galletta M; Grasso S; Vaiarelli A; Roseff SJ
    Eur Rev Med Pharmacol Sci; 2011 Oct; 15(10):1212-4. PubMed ID: 22165685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial.
    Colazingari S; Treglia M; Najjar R; Bevilacqua A
    Arch Gynecol Obstet; 2013 Dec; 288(6):1405-11. PubMed ID: 23708322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS.
    Facchinetti F; Bizzarri M; Benvenga S; D'Anna R; Lanzone A; Soulage C; Di Renzo GC; Hod M; Cavalli P; Chiu TT; Kamenov ZA; Bevilacqua A; Carlomagno G; Gerli S; Oliva MM; Devroey P
    Eur J Obstet Gynecol Reprod Biol; 2015 Dec; 195():72-76. PubMed ID: 26479434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach.
    Laganà AS; Garzon S; Casarin J; Franchi M; Ghezzi F
    Trends Endocrinol Metab; 2018 Nov; 29(11):768-780. PubMed ID: 30270194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experts' opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond.
    Facchinetti F; Appetecchia M; Aragona C; Bevilacqua A; Bezerra Espinola MS; Bizzarri M; D'Anna R; Dewailly D; Diamanti-Kandarakis E; Hernández Marín I; Kamenov ZA; Kandaraki E; Laganà AS; Monastra G; Montanino Oliva M; Nestler JE; Orio F; Ozay AC; Papalou O; Pkhaladze L; Porcaro G; Prapas N; Soulage CO; Stringaro A; Wdowiak A; Unfer V
    Expert Opin Drug Metab Toxicol; 2020 Mar; 16(3):255-274. PubMed ID: 32129111
    [No Abstract]   [Full Text] [Related]  

  • 15. Inositols' Importance in the Improvement of the Endocrine-Metabolic Profile in PCOS.
    Wojciechowska A; Osowski A; Jóźwik M; Górecki R; Rynkiewicz A; Wojtkiewicz J
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31752081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Myo-inositol in the treatment of polycystic ovary syndrome].
    Křepelka P
    Ceska Gynekol; 2014 Jun; 79(3):242-6. PubMed ID: 25054962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS.
    Pizzo A; Laganà AS; Barbaro L
    Gynecol Endocrinol; 2014 Mar; 30(3):205-8. PubMed ID: 24351072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients.
    Genazzani AD; Prati A; Santagni S; Ricchieri F; Chierchia E; Rattighieri E; Campedelli A; Simoncini T; Artini PG
    Gynecol Endocrinol; 2012 Dec; 28(12):969-73. PubMed ID: 22612517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients.
    Minozzi M; Nordio M; Pajalich R
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17(4):537-40. PubMed ID: 23467955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inositols in Polycystic Ovary Syndrome: An Overview on the Advances.
    Facchinetti F; Unfer V; Dewailly D; Kamenov ZA; Diamanti-Kandarakis E; Laganà AS; Nestler JE; Soulage CO;
    Trends Endocrinol Metab; 2020 Jun; 31(6):435-447. PubMed ID: 32396844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.